课题基金 / 基金详情

Project 2: Epigenetic ontogeny of vaccine response, susceptibility to respiratory infectious disease and asthma

Project 2: Epigenetic ontogeny of vaccine response, susceptibility to respiratory infectious disease and asthma
项目2:疫苗反应、呼吸道传染病和哮喘易感性的表观遗传个体发育
批准号:
10589821
负责人:
Tobias R. Kollmann
金额:
$12.62万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-03-10 至 2027-02-28

项目摘要

项目成果

Tobias R. Kollmann的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
SUMMARY – Project 2 (PR2) Early life microbial exposures can shape an individual’s basal immune state influencing acute responses to infections, vaccines and responses to environmental allergens. Perinatal microbial exposures are known to influence immune ontogeny and are linked to rising rates of allergy and asthma, yet mechanisms remain poorly defined. Colonisation of the mucosae by microbiota, vaccinations and systemic infections all modify immune ontogeny, but a mechanistic understanding of the combinatorial interactions of these events in the early life course, and their resulting programming effects on immune development in early life (IDEAL) are lacking. Project 2 (PR2) will investigate epigenetic mechanisms as a basis for understanding microbially-mediated programming of IDEAL. A growing body of work highlights an important role for epigenetic regulation of the genome in both central and peripheral immune cells following vaccination and infection. Dynamic changes in epigenetic modifications at gene enhancers and promoters in innate cells are mechanistically linked to pathogen recognition receptor (PRR) signalling. These mechanisms therefore bridge the microbial environment, host genome and immune ontogeny. Early life microbial exposures are a complex construct considering the broad scope of interactions and factors to consider. Yet our collaborators in the Clinical Core (CC; Lead Pichichero) have demonstrated reproducibly that some children display a phenotype of low production of protective antibody (Ab) levels to routine vaccinations with concomitant low cellular immune memory (low vaccine responders, LVR), whilst others exhibit robust protective immunity (high vaccine responders, HVR). In addition to this, some children are prone to recurrent respiratory infections (infection prone, IP) whilst others with similar pathogen burden are resilient (non-infection prone, NIP). These phenotypic subgroups will be capitalized upon as latent variables that reflect the construct of microbially-mediated immune programming through a latent class analysis. The overall effort will define trajectories of mucosal and systemic (e.g., immune ontogeny and microbiome across our IDEAL Meta Cohort (IMC) comprised of four diverse longitudinal childhood cohorts in relation to VR, IP and asthma. Epigenome-wide association analysis will identify methylation-sensitive genes that characterize trajectories of IDEAL. We posit that these phenotypes and sub-phenotypes of IDEAL contribute to the development of childhood illness and will therefore identify methylation-sensitive genes associated with IDEAL trajectories that predict endotypes and sub-phenotypes of VR, IP and asthma. We consider endotypes are likely to have distinct pathophysiology mechanisms and that epigenetic biomarkers of microbially-mediated immune programming can provide early detection as well as novel targets for precision interventions. Outcomes from PR2 will include enhanced mechanistic understanding of early immune programming, knowledge gains regarding genomic elements/pathways contributing to endotypes of VR, IP and asthma, prognostic biomarkers, and novel targets for preventive interventions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 2: Epigenetic ontogeny of vaccine response, susceptibility to respiratory infectious disease and asthma
  • 批准号:
    10435042
  • 项目类别:
  • 资助金额:
    $15.58万
  • 财政年份:
    2022
  • 负责人:
    Tobias R. Kollmann
  • 依托单位:
Immune status as a predictor of neonatal vaccine immunogenicity
  • 批准号:
    10063828
  • 项目类别:
  • 资助金额:
    $31.93万
  • 财政年份:
    2016
  • 负责人:
    Tobias R. Kollmann
  • 依托单位:
Immune status as a predictor of neonatal vaccine immunogenicity
  • 批准号:
    9245976
  • 项目类别:
  • 资助金额:
    $13.26万
  • 财政年份:
    2016
  • 负责人:
    Tobias R. Kollmann
  • 依托单位:
INDUCTION OF PROTECTIVE IMMUNITY TO LISTERIA IN NEONATES
  • 批准号:
    6916032
  • 项目类别:
  • 资助金额:
    $8.95万
  • 财政年份:
    2005
  • 负责人:
    Tobias R. Kollmann
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: